Biohaven: Despite Today's Gains, I Remain Skeptical
Biohaven Ltd. has provided an update on its research and development efforts, particularly focusing on its epilepsy asset and degrader programs. Despite recent gains, concerns remain regarding the company's significant accumulated deficit exceeding $2 billion. Upcoming pivotal data releases and ongoing projects in various therapeutic areas are critical for the company's future prospects.
- ▪Biohaven Ltd. shared an R&D presentation regarding its epilepsy asset and degrader programs.
- ▪The company has an accumulated deficit of over $2 billion.
- ▪Notable upcoming catalysts include pivotal epilepsy topline data.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909332-biohaven-despite-todays-gains-i-remain-sceptical"},"author":{"@type":"Person","name":"Edmund…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
